Nova Scotia

Appili Therapeutics Joins Dr. Reddy’s, Global Response Aid, and FUJIFILM in Advancing Avigan® Tablets for the Potential Treatment of COVID-19

Friday, October 30, 2020 - 1:38pm

The agreements work together to coordinate and accelerate the worldwide development, commercialization, and distribution of Avigan tablets (favipiravir) for the potential treatment and prevention of COVID-19.

Key Points: 
  • The agreements work together to coordinate and accelerate the worldwide development, commercialization, and distribution of Avigan tablets (favipiravir) for the potential treatment and prevention of COVID-19.
  • The clinical development strategy will focus on evaluating Avigan tablets for early treatment and post-exposure prophylaxis in the community setting.
  • In collaboration with its partners, Appili will design and oversee Phase 3 clinical trials to support regulatory submissions worldwide.
  • In addition, the Company is also testing FUJIFILM Toyama Chemical Inc.s drug Avigan for the potential treatment and prevention of COVID-19.

Conservation Partnership: Ducks Unlimited Canada teams up with Port Morien Wildlife Association to protect 122 acres of land in Black Brook, Cape Breton

Thursday, October 29, 2020 - 5:19pm

Black Brook, Cape Breton, Nova Scotia, Oct. 29, 2020 (GLOBE NEWSWIRE) -- October 29, 2020

Key Points: 
  • Black Brook, Cape Breton, Nova Scotia, Oct. 29, 2020 (GLOBE NEWSWIRE) -- October 29, 2020
    Black Brook, Cape Breton, Nova Scotia Ducks Unlimited Canada (DUC) has accepted a land donation in Black Brook, Cape Breton, Nova Scotia thanks to the generosity of four landowners.
  • Conserving this important area is now a shared effort with the Port Morien Wildlife Association (PMWA).
  • We could accept the land donation, being a non-profit charitable organization, and Port Morien Wildlife Association could utilize the property for conservation outreach activities and help us maintain it, says Lee Millett, conservation programs specialist with DUC.
  • We wanted to see the land protected into the future, so we contacted Ducks Unlimited Canada about the donation.

IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers Associated With Clinical Response in Patients With r/r DLBCL treated with DPX-Survivac Combination Therapy

Thursday, October 29, 2020 - 11:05am

ET to discuss the companys third quarter 2020 financial and operational results and to present biomarkers associated with clinical response in patients with relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL) and treated with DPX-Survivac Combination Therapy.

Key Points: 
  • ET to discuss the companys third quarter 2020 financial and operational results and to present biomarkers associated with clinical response in patients with relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL) and treated with DPX-Survivac Combination Therapy.
  • After the poster presentation and discussion of the above-mentioned data, IMV will then proceed with the presentation of third quarter financial and operational results.
  • The webcast will be recorded and will then be available on the IMV website for 30 days following the call.
  • IMV is currently assessing DPX-Survivac in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck.

Appili Therapeutics Appoints Drug Development Executive Don Cilla to the Newly Created Position of Chief Development Officer

Thursday, October 29, 2020 - 11:17am

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it has recruited Don Cilla, PharmD, MBA, to serve as the Companys new Chief Development Officer (CDO), effective November 1, 2020.

Key Points: 
  • Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it has recruited Don Cilla, PharmD, MBA, to serve as the Companys new Chief Development Officer (CDO), effective November 1, 2020.
  • In this role, Dr. Cilla will oversee the strategy and execution of the preclinical and clinical programs for Appilis anti-infective pipeline.
  • He brings to this role more than 30 years of experience in the drug development industry spanning large, midsize, and start-up companies, with extensive global clinical development and regulatory expertise.
  • His well-established track record developing a broad range of drug products in early and later phase development will be a tremendous asset to the Appili team.

Appili Therapeutics to Present at TSX Life Sciences Investor Day

Tuesday, October 27, 2020 - 4:30pm

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on anti-infective drug development, announced today that Appilis CEO Dr. Armand Balboni will be presenting at the first-ever Life Science Investor Day Virtual Conference hosted by TSX.

Key Points: 
  • Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on anti-infective drug development, announced today that Appilis CEO Dr. Armand Balboni will be presenting at the first-ever Life Science Investor Day Virtual Conference hosted by TSX.
  • Presentation details are as follows:
    Those interested in the presentation can click this hyperlink to register and access the webcast.
  • The Toronto Stock Exchange is hosting its first-ever Virtual TSX Life Sciences Investor Day conference.
  • The participants represent the next wave of innovation in the life science sector and will be showcasing the innovation and growth opportunities in Canada's Life Sciences sector.

Appili Therapeutics Announces Additional Funding for Its ATI-1701 Biodefense Program

Tuesday, October 27, 2020 - 12:30pm

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced updates for the continued development of its ATI-1701 biodefense vaccine program.

Key Points: 
  • Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced updates for the continued development of its ATI-1701 biodefense vaccine program.
  • DTRA-funded manufacturing work will be used to provide vaccine supply for future development of Appilis ATI-1701 program.
  • ATI-1701 has the potential to address this critical biodefense gap and we are eager to start the next stage of its development, said Dr. Armand Balboni, CEO of Appili Therapeutics .
  • Appili has built a pipeline of assets designed to address a broad range of significant unmet medical needs in the infectious disease landscape.

WildBrain Announces Conference Call for its Fiscal 2021 Q1 Results

Tuesday, October 27, 2020 - 10:00am

At WildBrain we inspire imaginations to run wild, engaging kids and families everywhere with great content across all media.

Key Points: 
  • At WildBrain we inspire imaginations to run wild, engaging kids and families everywhere with great content across all media.
  • Our television group owns and operates four family entertainment channels that are among the most viewed in Canada.
  • WildBrain is headquartered in Canada with offices worldwide and trades on the Toronto Stock Exchange (TSX: WILD).
  • Actual results or events may differ materially from those expressed or implied by such forward-looking statements.

National Police Federation Supports Launch of Nova Scotia Public Inquiry

Friday, October 23, 2020 - 11:30am

OTTAWA, ON, Oct. 23, 2020 /CNW/ - Following is a statement from Brian Sauv, President, National Police Federation, regarding the Nova Scotia Public Inquiry into Canada's largest mass shooting:

Key Points: 
  • OTTAWA, ON, Oct. 23, 2020 /CNW/ - Following is a statement from Brian Sauv, President, National Police Federation, regarding the Nova Scotia Public Inquiry into Canada's largest mass shooting:
    The National Police Federation welcomes yesterday's appointment of Dr. Kim Stanton as the third Commissioner in the Nova Scotia Public Inquiry, and is calling on the federal and provincial governments to begin the process without further delay.
  • As the labour relations representative for the 1,060 front-line Membersof the RCMP in Nova Scotia, the NPF will be applying for intervenor status to engage in the Inquiry.
  • About the National Police Federation:
    The National Police Federation (NPF) was certified to represent ~20,000 RCMP members serving across Canada and internationally in the summer of 2019.
  • The NPF is the largest police labour relations organization in Canada, the second largest in North America, and is the first independent national association to represent RCMP members.

Governments of Canada and Nova Scotia establish joint public inquiry in response to April tragedy

Thursday, October 22, 2020 - 7:55pm

OTTAWA, ONand HALIFAX, NS, Oct. 22, 2020 /CNW/ - The joint public inquiry in response to the April tragedy in Nova Scotia has been established and the Commissioners will now begin their work.

Key Points: 
  • OTTAWA, ONand HALIFAX, NS, Oct. 22, 2020 /CNW/ - The joint public inquiry in response to the April tragedy in Nova Scotia has been established and the Commissioners will now begin their work.
  • The Governments of Canada and Nova Scotia announced their intent to establish a comprehensive joint public inquiry in July.
  • The Joint Public Inquiry Commissioners' first task is setting up their Secretariat which will be located in Nova Scotia.
  • This Public Inquiry will play a critical role in the ongoing response to establish the facts and circumstances of this tragedy.

RCMP's response to the ongoing fisheries dispute in Nova Scotia

Wednesday, October 21, 2020 - 9:34pm

I will begin by assuring the people of Nova Scotia - and all Canadians that we are fully committed to keeping the peace, keeping people safe and enforcing the law.

Key Points: 
  • I will begin by assuring the people of Nova Scotia - and all Canadians that we are fully committed to keeping the peace, keeping people safe and enforcing the law.
  • I will begin by assuring the people of Nova Scotia - and all Canadians that we are fully committed to keeping the peace, keeping people safe and enforcing the law.
  • The Nova Scotia RCMP has launched investigations into a number of incidents with two people already charged including the assault against Chief Sack.
  • Investigations are ongoing and I encourage anyone with any information to contact the Nova Scotia RCMP.